Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors

.flex_column.av-s3q6d-55d0739350db1bc03ec0182f4f5653f8{ border-radius:0px 0px 0px 0px; padding:0px 0px 0px 0px; } #top .av-special-heading.av-3551wc-af1ea2b25223b2b9fd77c8c8b99f2d39{ padding-bottom:10px; } body .av-special-heading.av-3551wc-af1ea2b25223b2b9fd77c8c8b99f2d39 .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-3551wc-af1ea2b25223b2b9fd77c8c8b99f2d39 .av-subheading{ font-size:16px; } Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors – Series B proceeds will fund clinical proof-of-biology studies of SARM1 inhibitors –